Skip to main content
MANE
NYSE Life Sciences

Veradermics 10-Q: $798.4M Cash Into 2030, Q3 Loss $21.0M, New 10b5-1 Plans

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$148.44
Mkt Cap
$6.202B
52W Low
$32
52W High
$152.82
52W Position info
364% above low
Off High info
2.9% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MANE has more than doubled off its 52-week low of $32.

Summary

Veradermics' Q3 10-Q details a $21.0M quarterly loss and $798.4M in cash and securities it says funds operations into 2030, plus new 10b5-1 selling plans for two executives and a September 2026 patent review petition.


Key Events · Earnings and Guidance · MANE

  • Q3 Loss and Cash Confirmed in Full 10-Q

    Net loss of $20,999 thousand for the quarter and $71,733 thousand for nine months, with $798.4 million in cash, cash equivalents and marketable securities at September 30, 2026.

  • Runway Stated Into 2030

    Management says existing cash and securities fund operating expenses and capital expenditures into 2030; nine-month operating cash burn was $58,603 thousand versus $47,974 thousand a year earlier.

  • Two New Executive Selling Plans

    Mark Neumann adopted a Rule 10b5-1 plan on 08/13/2026 for up to 80,000 shares and CFO Dominic Carrano adopted one on 09/21/2026 for up to 42,000 shares, both sales beginning in December 2026.

  • Patent Post-Grant Review Petition Disclosed

    A third party filed a petition in September 2026 seeking post-grant review of one of the company's issued U.S. patents; the company says it intends to defend the patent vigorously.


Analysis · MANE · Life Sciences

The headline numbers were pre-released in this morning's 8-K, so the loss and cash balance are not new. What the full 10-Q adds is the detail behind them: nine-month operating cash burn of $58.6M against a $798.4M cash and securities pile that management says funds operations into 2030, which removes any near-term financing need even as R&D and pre-commercial G&A spending climb. It also puts two new insider selling plans on the record — the Chief Commercial and Strategy Officer for up to 80,000 shares and the CFO for up to 42,000 — and discloses that a third party filed a post-grant review petition in September 2026 against one of the company's issued U.S. patents, a patent risk that was not previously public.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MANE was trading at $148.44 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $32.00 to $152.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Nov 10, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $142.72
Real-time Price: $152.55 info
Change: +$9.83 (+7%) info
Market Cap: $6.374B info
MANE
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $142.00
Real-time Price: $152.55 info
Change: +$10.55 (+7%) info
Market Cap: $6.374B info
MANE
Nov 08, 2026, 6:00 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $139.33
Real-time Price: $152.55 info
Change: +$13.22 (+9%) info
Market Cap: $6.374B info
MANE
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $108.01
Real-time Price: $152.55 info
Change: +$44.54 (+41%) info
Market Cap: $6.374B info
MANE
Oct 18, 2026, 6:00 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $108.82
Real-time Price: $152.55 info
Change: +$43.73 (+40%) info
Market Cap: $6.374B info